[Experiences with panthesin-hydergine (PH 203) and exacthin (ACTH) in disorders of retinal circulation].
D000324:Adrenocorticotropic Hormone / Q000628:therapy*; D004088:Dihydroergotoxine; D004338:Drug Combinations; D004877:Ergoloid Mesylates; D004876:Ergot Alkaloids / Q000628:therapy*; D007930:Leucine / Q000031:analogs & derivatives; D011343:Procaine / Q000031:analogs & derivatives; D012160:Retina / Q000098:blood supply*; D062366:para-Aminobenzoates
D004338:Drug Combinations; D004876:Ergot Alkaloids; C006783:dihydroergotoxin, p-aminobenzoyl-N-diethyl-leucinol drug combination; D062366:para-Aminobenzoates; D004088:Dihydroergotoxine; D011343:Procaine; C005426:leucinocaine mesylate; D004877:Ergoloid Mesylates; D000324:Adrenocorticotropic Hormone; D007930:Leucine
CORTICOTROPIN/therapy; ERGOT ALKALOIDS/therapy; PARA-AMINOBENZOIC ACID/related compounds; RETINA/blood supply